Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax.
Vincenzo Maria PerrielloLorenza FaliniLoredana RuggeriDaniele SorciniStelvio BallantiLeonardo FlenghiNicodemo BaffaPiero CovarelliPaolo SportolettiAntonio PieriniBrunangelo FaliniPublished in: EJHaem (2023)